Bicara Therapeutics Inc. (BCAX) stock
BCAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.75−0.27 (-2.69%)
Close on Nov 16, 2026Market cap $645.19MP/E –Yield –
Earnings
Bicara Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 29, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$1.04
-$0.67 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Bicara Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 29, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 9, 2026before the open | – | – | -$1.04 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 11, 2026before the open | – | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 11, 2026before the open | – | – | -$0.93 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 30, 2026before the open | – | – | -$0.68 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 10, 2025before the open | – | – | -$0.67 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 12, 2025before the open | – | – | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 13, 2025before the open | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 27, 2025before the open | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024before the open | – | – | -$1.60 | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Bicara Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Bicara Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Bicara Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of DirectorsUpdate
- News
- Results
- Results
- News
- News
- Update
- Update
- Results
- Results
- Results
- Results
- Update
See a number that looks wrong?